Company news

C4 Therapeutics, Inc. news in 2023

C4 Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

December 11, 2023

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

December 11, 2023

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

November 27, 2023

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

November 19, 2023

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

October 31, 2023

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple My...

October 10, 2023

C4 Therapeutics Announces Chief Financial Officer Succession

September 4, 2023

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 7, 2023

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 16, 2023

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

July 4, 2023

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

June 19, 2023

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

May 29, 2023

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 3, 2023

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

April 18, 2023

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

February 22, 2023

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

February 7, 2023

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

January 29, 2023

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

January 8, 2023

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Decks in 2023